Diagnostic Approach for Suspected Rifampicin Resistance in TB Patients

Initial Diagnostic Strategy

For patients with prior TB treatment suspected of rifampicin resistance, the American Thoracic Society recommends performing GeneXpert MTB/RIF immediately on respiratory specimens while simultaneously sending samples for liquid culture with phenotypic drug susceptibility testing, then starting standard four-drug first-line therapy pending confirmatory results 1, 2
The World Health Organization recommends using GeneXpert MTB/RIF as the primary rapid diagnostic test because it provides results within hours rather than weeks, with pooled sensitivity of 89% and specificity of 99% for TB detection, and >97% sensitivity and specificity for rifampicin resistance detection 1, 3, 4

The Centers for Disease Control and Prevention recommend collecting at least 2-3 sputum specimens on different days for comprehensive testing 6
The European Respiratory Society recommends sending one specimen immediately for GeneXpert MTB/RIF testing and simultaneously submitting samples for liquid culture (MGIT) and phenotypic DST 1, 2, 5

The American College of Chest Physicians recommends starting standard four-drug first-line therapy immediately (rifampicin, isoniazid, pyrazinamide, ethambutol) while awaiting confirmatory phenotypic DST results 2

The Infectious Diseases Society of America warns against starting MDR-TB treatment based solely on GeneXpert rifampicin resistance without phenotypic confirmation, as this causes unnecessary toxicity and is explicitly not recommended 1, 2

The World Health Organization states that rapid molecular DST is an adjunct, not a replacement for culture-based DST, because it only evaluates rifampicin and occasionally isoniazid resistance, and effective MDR-TB treatment regimens require comprehensive DST information for all second-line drugs 1, 2, 3, 6